drugset / Trial / NCT07638371
FORTRAS: A Study of MSK-TCR5 in People With Solid Tumor Cancers
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to test the safety of MSK-TCR5 in participants with advance solid tumor cancer that has a KRAS, HRAS, or NRAS G12D mutation.
Timeline
- Start
- 2026-06-09
- Primary completion
- 2030-06-09
- Completion
- 2030-06-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MSK-TCR5 | Cell therapy | 3e+09 cells | — |
| Subject | MSK-TCR5 | Cell therapy | 1e+10 cells | — |
| Subject | MSK-TCR5 | Cell therapy | 3e+10 cells | — |
| Subject | MSK-TCR5 | Cell therapy | 1e+11 cells | — |